Intracellular Wnt/beta-catenin signaling underlying 17beta-estradiol-induced matrix metalloproteinase 9 expression in human endometriosis

Biology of Reproduction

Volumn 94, Issue 3, 2016, Pages

  Zhang, Ling ^a   Xiong, Wenqian ^a   Xiong, Yao ^a   Liu, Hengwei ^a   Li, Na ^a   Du, Yu ^a   Liu, Yi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Endometriosis; Estrogen; Estrogen receptor; Matrix metalloproteinase 9; Wnt signaling; catenin

Indexed keywords

BETA CATENIN; ESTRADIOL; GELATINASE B; LUCIFERASE; LYMPHOID ENHANCER FACTOR 1; TRANSCRIPTION FACTOR 7 LIKE 1; WNT PROTEIN; ESTROGEN RECEPTOR ALPHA; MMP9 PROTEIN, HUMAN;

ADULT; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOMETRIOSIS; ENDOMETRIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; LUCIFERASE ASSAY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; WNT SIGNALING PATHWAY; BINDING SITE; CELL INVASION; CELL MIGRATION; FEMALE INFERTILITY; GENE EXPRESSION; HUMAN CELL; INTRACELLULAR SIGNALING; PATHOGENESIS; REGULATORY MECHANISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADULT; BETA CATENIN; ENDOMETRIOSIS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MATRIX METALLOPROTEINASE 9; PROMOTER REGIONS, GENETIC; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 85007500573     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.115.135574     Document Type: Article

References (52)

1. Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010; 29:285-293.
2. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009; 26:19-34.
3. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174.
4. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278:16-27.
5. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002; 70:561-573.
6. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6:480-498.
7. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52:701-708.
8. Swiersz LM. Role of endometriosis in cancer and tumor development. Ann N Y Acad Sci 2002; 955:281-292 (discussion 293-285, 396-406).
9. Gaetje R, Kotzian S, Herrmann G, Baumann R, Starzinski-Powitz A. Invasiveness of endometriotic cells in vitro. Lancet 1995; 346:1463-1464.
10. Giudice LC, Kao LC. Endometriosis. Lancet 2004; 364:1789-1799.
11. Collette T, Bellehumeur C, Kats R, Maheux R, Mailloux J, Villeneuve M, Akoum A. Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9. Hum Reprod 2004; 19: 1257-1264.
12. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002; 2:289-300.
13. Chen X, Su Y, Fingleton B, Acuff H, Matrisian LM, Zent R, Pozzi A. Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. Int J Cancer 2005; 116:52-61.
14. Collette T, Maheux R, Mailloux J, Akoum A. Increased expression of matrix metalloproteinase-9 in the eutopic endometrial tissue of women with endometriosis. Hum Reprod 2006; 21:3059-3067.
15. Machado DE, Berardo PT, Palmero CY, Nasciutti LE. Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. J Exp Clin Cancer Res 2010; 29:4.
16. Chung HW, Wen Y, Chun SH, Nezhat C, Woo BH, Polan ML. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: a rationale for endometriotic invasiveness. Fertil Steril 2001; 75:152-159.
17. Pan H, Sheng JZ, Tang L, Zhu R, Zhou TH, Huang HF. Increased expression of c-fos protein associated with increased matrix metalloproteinase- 9 protein expression in the endometrium of endometriotic patients. Fertil Steril 2008; 90:1000-1007.
18. Becker CM, Louis G, Exarhopoulos A, Mechsner S, Ebert AD, Zurakowski D, Moses MA. Matrix metalloproteinases are elevated in the urine of patients with endometriosis. Fertil Steril 2010; 94:2343-2346.
19. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2002; 83:149-155.
20. Zylberberg C, Seamon V, Ponomareva O, Vellala K, Deighan M, Azzarolo AM. Estrogen up-regulation of metalloproteinase-2 and -9 expression in rabbit lacrimal glands. Exp Eye Res 2007; 84:960-972.
21. Hwang J, Hodis HN, Hsiai TK, Asatryan L, Sevanian A. Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: the modulating effect of statins. Atherosclerosis 2006; 189:76-82.
22. Kousidou O, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN, Karamanos NK. Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2008; 2:223-232.
23. Yang M, Jiang C, Chen H, Nian Y, Bai Z, Ha C. The involvement of osteopontin and matrix metalloproteinase- 9 in the migration of endometrial epithelial cells in patients with endometriosis. Reprod Biol Endocrinol 2015; 13:95.
24. Gold SM, Sasidhar MV, Morales LB, Du S, Sicotte NL, Tiwari-Woodruff SK, Voskuhl RR. Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERa). Lab Investig 2009; 89:1076-1083.
25. Lee JY, Choi HY, Na WH, Ju BG, Yune TY. 17beta-estradiol inhibits MMP-9 and SUR1/TrpM4 expression and activation and thereby attenuates BSCB disruption/hemorrhage after spinal cord injury in male rats. Endocrinology 2015; 156:1838-1850.
26. Matsuzaki S, Darcha C. Involvement of the Wnt/beta-catenin signaling pathway in the cellular and molecular mechanisms of fibrosis in endometriosis. PLoS One 2013; 8:e76808.
27. Cheng CW, Smith SK, Charnock-Jones DS. Transcript profile and localization of Wnt signaling-related molecules in human endometrium. Fertil Steril 2008; 90:201-204.
28. Wu Y, Kajdacsy-Balla A, Strawn E, Basir Z, Halverson G, Jailwala P, Wang Y, Wang X, Ghosh S, Guo SW. Transcriptional characterizations of differences between eutopic and ectopic endometrium. Endocrinology 2006; 147:232-246.
29. Valenta T, Hausmann G, Basler K. The many faces and functions of betacatenin. EMBO J 2012; 31:2714-2736.
30. Matsuzaki S, Botchorishvili R, Pouly JL, Canis M. Targeting the Wnt/ beta-catenin pathway in endometriosis: a potentially effective approach for treatment and prevention. Mol Cell Ther 2014; 2:36.
31. Lee MA, Park JH, Rhyu SY, Oh ST, Kang WK, Kim HN. Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. BMC Cancer 2014; 14:125.
32. Song Y, Yang QX, Zhang F, Meng F, Li H, Dong Y, Han A. Suppression of nasopharyngeal carcinoma cell by targeting beta-catenin signaling pathway. Cancer Epidemiol 2012; 36:e116-e121.
33. Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 2007; 26:227-239.
34. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817-821.
35. Mizumoto H, Saito T, Ashihara K, Nishimura M, Takehara M, Tanaka R, Ito E, Kudo R. Expression of matrix metalloproteinases in ovarian endometriomas: immunohistochemical study and enzyme immunoassay. Life Sci 2002; 71:259-273.
36. Huhtinen K, Desai R, Stahle M, Salminen A, Handelsman DJ, Perheentupa A, Poutanen M. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. J Clin Endocrinol Metab 2012; 97:4228-4235.
37. Kvaskoff M, Mu F, Terry KL, Harris HR, Poole EM, Farland L, Missmer SA. Endometriosis: a high-risk population for major chronic diseases? Hum Reprod Update 2015; 21:500-516.
38. Pavone ME, Lyttle BM. Endometriosis and ovarian cancer: links, risks, and challenges faced. Int J Womens Health 2015; 7:663-672.
39. Han SJ, O'Malley BW. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum Reprod Update 2014; 20:467-484.
40. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516.
41. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5:691-701.
42. Anastas JN, Randall TM. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13:12-26.
43. Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 2013; 48:222-272.
44. Nissinen L, Kahari VM. Matrix metalloproteinases in inflammation. Biochim Biophys Acta 2014; 1840:2571-2580.
45. Gaide Chevronnay HP, Selvais C, Emonard H, Galant C, Marbaix E, Henriet P. Regulation of matrix metalloproteinases activity studied in human endometrium as a paradigm of cyclic tissue breakdown and regeneration. Biochim Biophys Acta 2012; 1824:146-156.
46. Cox KE, Piva M, Sharpe-Timms KL. Differential regulation of matrix metalloproteinase-3 gene expression in endometriotic lesions compared with endometrium. Biol Reprod 2001; 65:1297-1303.
47. Hudelist G, Keckstein J, Czerwenka K, Lass H, Walter I, Auer M, Wieser F, Wenzl R, Kubista E, Singer CF. Estrogen receptor beta and matrix metalloproteinase 1 are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis. Fertil Steril 2005; 84(Suppl 2):1249-1256.
48. Hudelist G, Lass H, Keckstein J, Walter I, Wieser F, Wenzl R, Mueller R, Czerwenka K, Kubista E, Singer CF. Interleukin 1alpha and tissue-lytic matrix metalloproteinase-1 are elevated in ectopic endometrium of patients with endometriosis. Hum Reprod 2005; 20:1695-1701.
49. Malvezzi H, Aguiar VG, Paz CC, Tanus-Santos JE, Penna IA, Navarro PA. Increased circulating MMP-2 levels in infertile patients with moderate and severe pelvic endometriosis. Reprod Sci 2013; 20:557-562.
50. Matsuzaki S, Maleysson E, Darcha C. Analysis of matrix metalloproteinase- 7 expression in eutopic and ectopic endometrium samples from patients with different forms of endometriosis. Hum Reprod 2010; 25:742-750.
51. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141:52-67.
52. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006; 6:227-239.